Corcept Therapeutics announced the publication of findings from the prevalence phase of its CATALYST trial in Diabetes Care, a peer-reviewed journal of the American Diabetes Association. The article, titled 'Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes,' provides scientific validation for the study's significant findings.
The CATALYST trial, the largest and most rigorous study of its kind, screened 1,057 patients with difficult-to-control type 2 diabetes and found that 24 percent of these patients had hypercortisolism. This finding indicates a much higher prevalence of the condition than previously recognized within this patient population.
The publication is expected to increase awareness among clinicians about hypercortisolism as an underlying cause of inadequately controlled type 2 diabetes. This increased understanding could lead to expanded screening and diagnosis, thereby broadening the addressable market for Corcept's cortisol-modulating therapies like Korlym.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.